Moreover, Herbst and his colleagues analyzed baseline tumor‐associated immune cells in biopsy specimens of patients treated with anti‐PD‐1 antibodies (PD‐1 mAb) and reported that non‐responders were more likely lacking CD8+ T cells within TME.11 Here, CD8A is linked to neoplasm.